Guideline for treating low bone density or osteoporosis to prevent fractures
The American College of Physicians recommends in an evidence-based clinical practice guideline that physicians treat women with osteoporosis with bisphosphonates (alendronate, risedronate, or zoledronic acid) or denosumab, a biologic agent. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 8, 2017 Category: Science Source Type: news
Amgen Presents New Data From Phase 3 XGEVA ® (denosumab) Study In Multiple Myeloma Patients At The 16th International Myeloma Workshop
In this study, XGEVA® (denosumab) met the primary endpoint, demonstrating non-inferiority to zoledronic acid in delaying the time to first on-study skeletal-related event (SRE) in patients with multiple myeloma (HR=0.98, 95 percent CI: 0.85, 1.... (Source: Amgen News Release)
Source: Amgen News Release - March 3, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen To Present New KYPROLIS ® (Carfilzomib) And XGEVA® (Denosumab) Data At The 16th International Myeloma Workshop
Detailed Results From Phase 3 Head-to-Head ENDEAVOR Trial Show KYPROLIS Significantly Improved Overall Survival Compared to Velcade® (Bortezomib) in Relapsed or Refractory Multiple Myeloma Patients
Late-Breaking Results From Largest International Trial Conducted in Multiple Myeloma Show XGEVA was Non-Inferior Versus Zoledronic Acid in Delaying Bone Complications
THOUSAND OAKS, Calif., March 1, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from the KYPROLIS® (carfilzomib) and XGEVA® (denosumab) clinical development programs will be presented at the 16th International Myeloma Workshop (IMW...
Source: Amgen News Release - March 1, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
New clinical trial to test drug combination to treat osteogenesis imperfecta
The University of Edinburgh will conduct a six-year trial of teriparatide and zoledronic acid combination to treat a condition called osteogenesis imperfecta (OI). (Source: Drug Development Technology)
Source: Drug Development Technology - January 18, 2017 Category: Pharmaceuticals Source Type: news
Reducing Zoledronic Acid Frequency Did Not Raise Risk of Skeletal Events
Among cancer patients with bone metastases, administration of zoledronic acid every 12 weeks did not increase the risk of skeletal events over 2 years compared with the standard dosing of every 4 weeks. (Source: CancerNetwork)
Source: CancerNetwork - January 6, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Bone Metastases Breast Cancer Multiple Myeloma News Prostate Cancer Source Type: news
Powerful Drug for Advanced Cancers May Need Less Frequent Dosing
Patients whose disease has spread to bone can cut side effects tied to zoledronic acid, researchers report
Source: HealthDay
Related MedlinePlus Pages: Bone Cancer, Breast Cancer, Prostate Cancer (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - January 4, 2017 Category: Consumer Health News Source Type: news
Powerful Drug for Advanced Cancers May Need Less Frequent Dosing
WEDNESDAY, Jan. 4, 2017 -- Use of a bone cancer drug once every three months, instead of monthly, does not boost the risk of bone problems over two years, a new study finds.
That could reduce side effects from the drug, known as zoledronic acid... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 4, 2017 Category: Journals (General) Source Type: news
Powerful Drug for Advanced Cancers May Need Less Frequent Dosing
Patients whose disease has spread to bone can cut side effects tied to zoledronic acid, researchers report (Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - January 4, 2017 Category: Cancer & Oncology Source Type: news
Powerful Drug for Advanced Cancers May Need Less Frequent Dosing
Patients whose disease has spread to bone can cut side effects tied to zoledronic acid, researchers report (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 3, 2017 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Family Medicine, Nursing, Oncology, Pharmacy, Rheumatology, News, Source Type: news
Longer Dosing Interval for Zoledronic Acid for Bone Mets Longer Dosing Interval for Zoledronic Acid for Bone Mets
Increasing the dosing interval of zoledronic acid did not cause an increase in skeletal events.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 3, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Docetaxel, zoledronic acid not cost effective for prostate cancer
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 31, 2016 Category: Drugs & Pharmacology Source Type: news
Non-TCA/SSRI Antidepressants Increase Fall Risk in Elderly Frail Women
Antidepressants from classes other than tricyclics (TCAs) and selective serotonin reuptake inhibitors (SSRIs) did not appear to reduce the risk for falls, according to results of the Zoledronic acid in frail Elders to STrengthen bone (ZEST) study. (Source: Caring for the Ages)
Source: Caring for the Ages - September 29, 2016 Category: Health Management Authors: Jason Harris Source Type: news
Make the Diagnosis: Bewildering Bone Pain
(MedPage Today) -- Case Findings: A 23-year-old male presents with a presumed diagnosis of vanishing bone disease (Gorham ' s disease), a rare condition in which bone is lost in conjunction with an overgrowth of lymphatic vessels. However, the patient presents with ongoing severe pain, which is uncommon in Gorham ' s disease. He was treated with interferon and zoledronic acid, but discontinued these treatments because of severe side effects.
What is your diagnosis? (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 26, 2016 Category: Cardiology Source Type: news
